|

Fruquintinib Clinical Trials

30 actively recruiting trials across 7 locations

Also known as: Adebrelimab, Elunate, Fruzaqla, Fruzaqla™, HMPL-013, Raltitrexed, TKI, high and low dose radiotherapy, hmpl-013

Other22 trials

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase 2
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Phase 2
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Phase 3
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Phase 2
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
N/A
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Phase 2
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Phase 2
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
Phase 4
Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study
Phase 2
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
N/A
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Phase 2
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Phase 2/3
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Phase 2
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Phase 2
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Phase 3
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase 2
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Phase 2

Birmingham, Alabama2 trials

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

University of Alabama

Phase 1
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Central Alabama Research

Phase 4

Aurora, Colorado1 trial

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

University of Colarodo Cancer Center

Phase 2

Denver, Colorado1 trial

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Rocky Mountain Cancer Center - Primary

Phase 2

Miami Beach, Florida1 trial

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Mount Sinai Cancer Research Program

Phase 2

Bay City, Michigan1 trial

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Karmanos Cancer Institute at McLaren Bay Region

Phase 2

New York, New York1 trial

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Columbia University Irving Medical Center

Phase 1/2

Houston, Texas1 trial

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.